ClinicalTrials.gg
RecruitingNCT07843329DARI-DREAMUpdated Nov 5, 2026

A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day

A Phase 3 interventional study of Daridorexant and Placebo in Insomia Disorder, sponsored by Idorsia Pharmaceuticals Ltd.. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 3, Interventional, and Treatment

Updated Nov 5, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this clinical trial is to collect more data about the effect of daridorexant in adults and elderly people with insomnia disorder.

The trial aims to find out whether daridorexant can help improve:

  • how trial participants sleep at night,
  • how trial participants function the next day.

Researchers will compare daridorexant to a placebo (a look-alike inactive substance that contains no active medicine) to understand which effect daridorexant has on total sleep time and next-day functioning.

Enrolled participants will:

  • Take daridorexant 50 mg or placebo once daily for approximately 3 months
  • Visit the clinic once every month during treatment for checkups and tests
  • Keep a sleep diary of the number of hours they sleep and how well they sleep
  • Complete a questionnaire every day about any symptoms of sleepiness during the day and any impact on physical and mental functioning such as energy levels, mood, or ability to concentrate or memorize.
Read the detailed description

The trial includes three trial periods:

Following a Screening period, during which it will be checked if participants are eligible to take part, eligible participants will be randomized in a 1:1 ratio to receive either daridorexant 50 mg or placebo for ca. 3 months (Treatment period). On completion of treatment, participants will be followed for up to 10 days for safety assessments (Safety follow-up period).

Trial participation will end with a Follow-up call (Participant Last Visit) at the end of the Safety follow-up period.

The maximum trial duration for an individual participant will be approximately 4 months.

02

Conditions studied

  • Insomia Disorder
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged ≥ 18 years at the time of signing the ICF
  • Insomnia disorder diagnosis according to the criteria including: Self-reported insufficient sleep quantity defined as subjective Total Sleep Time (TST) ≤ 6.5 hours during the night, associated with difficulties with sleep initiation or maintenance or early-morning awakenings, for at least 3 nights per week during a period of at least 3 months prior to screening visit
  • Insomnia Severity Index© score ≥ 15
  • Presence of insomnia symptoms (TST ≤ 6.5 hours for at least 3 valid nights recording, and average TST ≤ 6.5 hours over 7 nights) confirmed by objective measurements using a home electroencephalogram (EEG) device over a 7-night period during screening
  • Adequate opportunity for sleep (time in bed ≥ 7 hours for at least 3 valid recorded nights) confirmed by objective measurements obtained using the home EEG device during the 7-night assessment period specified in the inclusion criterion above

Exclusion criteria

Exclusion Criteria:

  • \< 18.5 or > 40.0 kg/m2
  • Any lifetime history of breathing-related sleep disorder
  • Presence of an additional sleep-wake disorder
  • Self-reported usual daytime napping ≥ 1 hour per day and ≥ 3 days per week
  • Previous treatment with daridorexant or other dual orexin receptor antagonists at any time prior to Visit 1
  • Acute or unstable (i.e., not adequately controlled for at least 1 month) psychiatric condition
  • Any suicidal ideation or history of suicide attempt, as assessed by Columbia Suicide Severity Rating Scale© (C-SSRS©), at Visit 1
  • Unstable medical condition, which, in the opinion of the investigator, could affect the participant's safety or interfere with the trial assessments
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
344 participants (estimated)

Study arms

  • Experimental
    Daridorexant

    Participants will receive 50 mg daridorexant orally, once daily for approximately 3 months.

    Drug: Daridorexant

  • Placebo comparator
    Placebo

    Participants will receive placebo orally, once daily for approximately 3 months.

    Drug: Placebo

Interventions

  • Daridorexant 50 mg tablets

  • DrugPlacebo

    Matching placebo tablets

06

What researchers measure

Primary outcomes

  1. Change from baseline to Month 3 in Subjective Total Sleep Time (sTST)

    Subjective Total Sleep Time (sTST) is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in sTST. A negative change from baseline indicates a decrease in sTST.

    Time frame: Baseline and Month 3

Secondary outcomes

  1. Change from baseline to Month 3 in Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Sleepiness Domain Score (SDS)

    The IDSIQ is a validated patient-reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., Alert/Cognition, Mood, and Sleepiness) reflecting daytime impairment of insomnia. The SDS ranges from 0 to 40. A higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

    Time frame: Baseline and Month 3

  2. Change from baseline to Month 3 in Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Total Score (TS)

    The IDSIQ comprises three domains: Alert/Cognition (maximum score: 60), Mood (maximum score: 40), and Sleepiness (maximum score: 40), resulting in a TS ranging from 0 to 140. A higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

    Time frame: Baseline and Month 3

07

Study locations

1 of 9 sites recruiting
  • Preferred Research Partners Inc.
    Little Rock, Arkansas 72211, United States
    Not yet recruiting
  • Synergy San Diego
    Lemon Grove, California 91945, United States
    Not yet recruiting
  • Empire Clinical Research
    Pomona, California 91767, United States
    Not yet recruiting
  • Teradan Clinical Trials, LLC
    Brandon, Florida 33511, United States
    Not yet recruiting
  • Hope Research Network
    Virginia Gardens, Florida 33166, United States
    Recruiting
  • Encore Medical Research, LLC - Weston
    Weston, Florida 33331, United States
    Not yet recruiting
  • Advanced Respiratory and Sleep Medicince LLC
    Huntersville, North Carolina 28078, United States
    Not yet recruiting
  • Eximia Research - NC, LLC
    Raleigh, North Carolina 27607, United States
    Not yet recruiting
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Nov 2027, 12 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 28, 2026
StartActual
Oct 28, 2026was Sep 2026
Primary completionEst.
Nov 22, 2027
CompletionEst.
Dec 6, 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
9 sites added — first site in United States
Show 9 added (9 United States)
  • Preferred Research Partners Inc. · Little Rock, United States
  • Synergy San Diego · Lemon Grove, United States
  • Empire Clinical Research · Pomona, United States
  • Teradan Clinical Trials, LLC · Brandon, United States
  • Hope Research Network · Virginia Gardens, United States
  • Encore Medical Research, LLC - Weston · Weston, United States
  • Advanced Respiratory and Sleep Medicince LLC · Huntersville, United States
  • Eximia Research - NC, LLC · Raleigh, United States
  • CTI Clinical Research Center · Cincinnati, United States
Nov 5, 2026
Start date
Sep 2026→Oct 28, 2026 (actual)
Nov 5, 2026
Registered
First appeared on the registry
Sep 28, 2026
Show all 2 updates
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    9 sites added — first site in United States
    Show 9 added (9 United States)
    • Preferred Research Partners Inc. · Little Rock, United States
    • Synergy San Diego · Lemon Grove, United States
    • Empire Clinical Research · Pomona, United States
    • Teradan Clinical Trials, LLC · Brandon, United States
    • Hope Research Network · Virginia Gardens, United States
    • Encore Medical Research, LLC - Weston · Weston, United States
    • Advanced Respiratory and Sleep Medicince LLC · Huntersville, United States
    • Eximia Research - NC, LLC · Raleigh, United States
    • CTI Clinical Research Center · Cincinnati, United States
    Start date Sep 2026→Oct 28, 2026 (now actual)
  2. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843329
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Oct 28, 2026
Primary completion
Nov 22, 2027 (estimated)
Completion
Dec 6, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Idorsia Clinical Trial Information USA
Contact
idorsiaclinicaltrials@idorsia.com
+1 856 661 37 21
Idorsia Clinical Trial Information Europe
Contact
idorsiaclinicaltrials@idorsia.com
+41 58 844 1977
Global Clinical Development
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion